Charles River Laboratories (CRL) Tops Q4 EPS by 5c, Offers Guidance
Charles River Laboratories (NYSE: CRL) reported Q4 EPS of $2.46, $0.05 better than the analyst estimate of $2.41. Revenue for the quarter came in at $1.01 billion versus the consensus estimate of $991.25 million.
GUIDANCE:
Charles River Laboratories sees FY2024 EPS of $10.90-$11.40, versus the consensus of $10.79.
2024 GUIDANCE |
|
Revenue growth, reported | 1.0% – 4.0% |
Impact of divestitures/(acquisitions), net | ~(0.5)% |
(Favorable)/unfavorable impact of foreign exchange | ~(0.5)% |
Revenue growth, organic (1) | 0.0% – 3.0% |
GAAP EPS estimate | $7.90 – $8.40 |
Acquisition-related amortization (2) | ~$2.40 |
Acquisition and integration-related adjustments (3) | ~$0.10 |
Costs associated with restructuring actions (4) | ~$0.25 |
Other items (5) | ~$0.25 |
Non-GAAP EPS estimate | $10.90 – $11.40 |
For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.